Select Language
Claudin-18.2
Claudin-18.2 Overview
| English Name | Claudin-18 splice variant 2 | Approved Drugs | 1 |
| Drugs in Clinical Trials | 85 | Target Synonym | UNQ778/PRO1572，CLDN18，Claudin 18，Surfactant Associated Protein J，Surfactant， Pulmonary Associated Protein J，Surfactant Associated 5，Claudin-18，SFTA5，SFTPJ，Claudin 18.2，CLDN18.2 |
| Highest Development Stage | Approved | ||
| English Name | Claudin-18 splice variant 2 |
| Target Synonym | UNQ778/PRO1572，CLDN18，Claudin 18，Surfactant Associated Protein J，Surfactant， Pulmonary Associated Protein J，Surfactant Associated 5，Claudin-18，SFTA5，SFTPJ，Claudin 18.2，CLDN18.2 |
| Approved Drugs | 1 |
| Drugs in Clinical Trials | 85 |
| Highest Development Stage | Approved |
Claudin-18.2 Product List
- Product Category
Protein (11)Cell (1)Antibody (1)
- Product Status
Launched (13)
- Species
Human / Cynomolgus (6)Human (4)Mouse (3)
- Tag
His Tag & Strep Tag (3)- (8)GFP Tag (1)His Tag & Flag Tag (1)
- Conjugate
Unconjugated (7)- (1)GFP Fusion (1)Biotin-labeled (3)PE Labeled (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
HOT CL2-H52P7 |  Human | HEK293 | Human Claudin-18.2 Full Length Protein (VLP) |  | ||
HOT CL2-M5585 |  Mouse | InsectCells | Mouse Claudin-18.2 Protein, His,Twin-Strep Tag (Detergent) |  |  | |
HOT CL2-H5587 | Human / Cynomolgus | InsectCells | Human / Cynomolgus Claudin-18.2 Protein, His,Twin-Strep Tag (Detergent) |  | | |
HOT CL2-H85D3 | Human / Cynomolgus | InsectCells | Biotinylated Human / Cynomolgus Claudin-18.2 Protein, His,Avitag™&Flag Tag (Detergent) |  | | |
CHEK-ATP033 | Human | HEK293 | HEK293/Human Claudin-18.2 Stable Cell Line |  | ||
CL2-H82P3 | Human | HEK293 | Biotinylated Human Claudin-18.2 Full Length Protein (VLP) | | ||
CL2-HF218 | Human | HEK293 | Fluorescent Human Claudin-18.2 Full Length Protein (VLP) | | ||
CL2-M52P3 | Mouse | HEK293 | Mouse Claudin-18.2 Full Length Protein (VLP) | | ||
HCS-S278 | Mouse | - | Recombinant Monoclonal Anti-Claudin-18.2 Antibody, Mouse (3B10) | |||
CL2-H5586 | Human / Cynomolgus | InsectCells | Human / Cynomolgus Claudin-18.2 Protein, His,Twin-Strep Tag (Nanodisc) |  | |
Total: 13
- 1
- 2
Claudin-18.2 Background
Claudins (CLDNs) are a family of proteins that form tight junctions and maintain the polarity of epithelial and endothelial cells. CLDN18 is specifically expressed in the stomach and lung. Of the two CLDN18 isoform transcripts produced by alternative splicing, CLDN18.2 is a highly selective gastric lineage marker that determines the gastric phenotype in a neoplastic condition, whereas CLDN18.1 is lung specific. CLDN18.2 is a highly selective gastric lineage antigen expressed exclusively on short-lived differentiated gastric epithelial cells where it has only limited accessibility to antibody drugs.14,15 CLDN18.2 is maintained during the course of malignant transformation and thus frequently displayed on the surface of human gastric cancer cells.
Claudin-18.2 Synonyms
Claudin-18.2,CLDN18,Claudin-18
Antibody Project Trading Platform
| Project Name | Project Stage | Molecule Type | Molecule Source | Disease Area | Indication |
|---|---|---|---|---|---|
| CLDN18.2 CAR-T - 01 | PhaseI | CAR | Nanobody | Solid Tumor | Advanced refractory gastrointestinal tumors |
| CLDN18.2 VHH - 01 | Lead | Monoclonal | Nanobody | Solid Tumor | Gastric Cancer,Pancreatic cancer |
Project Cooperation
| Project Name | Drug Type | Therapeutic Area | Indication | Stage | Rights Area |
|---|---|---|---|---|---|
| Claudin18.2×CD8+ T bsAb | Bispecific antibody | Oncology/Cancer | Gastric cancer,Pancreatic cancer,Oophoroma | IND | Global |
| CLDN 18.2 CAR-T | Cell therapy | Oncology/Cancer | Gastric Cancer,Pancreatic Cancer | IND | Global |
| Claudin18.2 mAb | Monospecific antibody | Oncology/Cancer | Gastric cancer | Phase I | Global |
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Osemitamab | MSB-018; TST-001 | Phase 3 Clinical | HJB (Hangzhou) Co Ltd, Suzhou Transcenta Therapeutics Co Ltd | Biliary Tract Neoplasms; Esophageal Neoplasms; Gallbladder Neoplasms; Gastroesophageal Junction Neoplasms; Lung Neoplasms; Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| XNW-27011 | XNW-27011 | Phase 3 Clinical | Evopoint Biosciences Co Ltd | Adenocarcinoma; Biliary Tract Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Gastroesophageal Junction Neoplasms; Ovarian Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| IMC-002 (Suzhou Immunofoco) | IMC-002 | Phase 3 Clinical | Suzhou Immunofoco Biotechnology Co Ltd | Digestive System Neoplasms; Gastroesophageal Junction Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms | Details |
| Arcotatug tavatecan | IBI-343; IBI343 | Phase 3 Clinical | Innovent Biologics(Suzhou) Co Ltd | Adenocarcinoma; Carcinoma, Pancreatic Ductal; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| LB-4330 | LB-4330; Bis-2 | Phase 3 Clinical | L&L Biopharma Co Ltd | Solid tumours; Uterine Cervical Neoplasms | Details |
| JS-107 | JS-107; JS107 | Phase 3 Clinical | Shanghai Junshi Biosciences Co Ltd | Adenocarcinoma; Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Tecotabart vedotin | TPX-4589; BMS-986476; LM-302 | Phase 3 Clinical | LaNova Medicines Ltd | Adenocarcinoma; Digestive System Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Gastrointestinal Neoplasms; Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| QLS-31905 | QLS-31905 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Bile Duct Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| SYSA-1801 | SYSA1801; CPO-102; EO-3021; SYSA-1801 | Phase 3 Clinical | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd | Digestive System Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Gastrointestinal Neoplasms; Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Garetatug Rezetecan | SHR-A-1904; SHR-A1904 | Phase 3 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Bile Duct Neoplasms; Biliary Tract Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Lymphangioma, Cystic; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| FG-M-108 | FG-M-108; M108; M-108 | Phase 3 Clinical | FutureGen Biopharm (Beijing) Co Ltd | Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Sonesitatug Vedotin | CMG-901; CMG901; AZD-0901; AZD0901 | Phase 3 Clinical | Keymed Biosciences Co Ltd | Biliary Tract Neoplasms; Carcinoma, Pancreatic Ductal; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| ASKB-589 | ASKB-589 | Phase 3 Clinical | AskGene Pharma Inc, Jiangsu Aosaikang Pharmaceutical Co Ltd | Adenocarcinoma; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| KD-182 | KD-182 | Phase 2 Clinical | Nanjing Kaidi Medical Technology Co Ltd | Carcinoma, Pancreatic Ductal; Stomach Neoplasms | Details |
| CLDN18.2-TAC T cells Therapy | CLDN-18.2-TAC T cells; CLDN18.2-TAC T cells | Phase 2 Clinical | Triumvira Immunologics Inc | Solid tumours; Stomach Neoplasms | Details |
| HBM-7022 | HBM-7022; AZD-5863 | Phase 2 Clinical | Harbour Biomed | Carcinoma, Pancreatic Ductal; Esophageal adenocarcinoma; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms | Details |
| EB-DNK102 | EB-DNK102 | Phase 2 Clinical | Beijing Biotech | Carcinoma, Pancreatic Ductal | Details |
| Claudin18.2 targeting CAR-T cell therapy (Essen Biotech) | Phase 2 Clinical | Essen Biotech | Pancreatic Neoplasms | Details | |
| AZD-4360 | AZD4360; AZD-4360 | Phase 2 Clinical | Astrazeneca Ab | Biliary Tract Neoplasms; Carcinoma, Pancreatic Ductal; Gastroesophageal Junction Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| BDC-4182 | BD-4182; BDC-4182 | Phase 2 Clinical | Bolt Biotherapeutics Inc | Adenocarcinoma; Esophageal Neoplasms; Neoplasms; Stomach Neoplasms | Details |
| LCB-02A | LCB-02A | Phase 2 Clinical | Legochem Biosciences Inc | Hematologic Neoplasms; Solid tumours | Details |
| PM-1032 | PM1032; PM-1032 | Phase 2 Clinical | Shanghai Genechem Co Ltd | Neoplasms; Pancreatic Neoplasms | Details |
| Spevatamig | PT-886; PT886 | Phase 2 Clinical | Phanes Therapeutics Inc | Biliary Tract Neoplasms; Carcinoma, Pancreatic Ductal; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| SKB-315 | SKB-315; SKB315; MK1200; MK-1200 | Phase 2 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Esophageal Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| ATG-022 | ATG-022; ATN-022 | Phase 2 Clinical | Antengene Corporation Co Ltd | Gastroesophageal Junction Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| SOT-102 | SOT-102; SOT102; SO-N102 | Phase 2 Clinical | Sotio Biotech AG | Pancreatic Neoplasms; Stomach Neoplasms | Details |
| Givastomig | TJ-CD4B; ABL-111; TJ-CLDN4B; TJ-033721; TJ-CD4B/ABL111 | Phase 2 Clinical | I-Mab Biopharma Co Ltd | Biliary Tract Neoplasms; Carcinoma, Pancreatic Ductal; Esophageal adenocarcinoma; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Neoplasm Metastasis; Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Q-1802 | Q-1802 | Phase 2 Clinical | Qure Biotechnology (Shanghai) Co Ltd | Esophageal Neoplasms; Gastrointestinal Neoplasms; Solid tumours | Details |
| Recombinant humanized monoclonal antibody MIL93(Mabworks) | MIL-93 | Phase 2 Clinical | Beijing Mabworks Biotech Co Ltd | Gastroesophageal Junction Neoplasms; Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| RC-118 | RC-118; YH005 ADC | Phase 2 Clinical | Gastroesophageal Junction Neoplasms; Solid tumours; Stomach Neoplasms | Details | |
| Recombinant humanized anti-Claudin 18.2 monoclonal antibody (CARsgen) | AB-011 | Phase 1 Clinical | Carsgen Biomedicine (Shanghai) Co Ltd, Kaixing Life Technology (Shanghai) Co Ltd | Esophageal Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| KD-496 | KD-496(4th); KD-496 | Phase 1 Clinical | Nanjing Kaidi Medical Technology Co Ltd | Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Claudin18.2 Targeted CAR-T Cells therapy (Frontiergate Biopharm) | Phase 1 Clinical | Frontiergate Biopharm (Hainan) Co Ltd | Pancreatic Neoplasms | Details | |
| Claudin18.2 Targeted Activated Dendritic Cells therapy (Frontiergate Biopharm) | Phase 1 Clinical | Frontiergate Biopharm (Hainan) Co Ltd | Pancreatic Neoplasms | Details | |
| CBG-131 | CBG-131; CBG131 | Phase 1 Clinical | Carbiogene Therapeutics Co Ltd | Pancreatic Neoplasms; Stomach Neoplasms | Details |
| Claudin18.2 CAR-T cell therapy (Ucello Therapeutics) | Phase 1 Clinical | Ucello Therapeutics Co Ltd | Solid tumours | Details | |
| Gresonitamab | AMG-910 | Phase 1 Clinical | Amgen Inc | Adenocarcinoma; Esophageal Neoplasms; Stomach Neoplasms | Details |
| Claudin18.2-targeted CAR-DCs therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine) | Phase 1 Clinical | Second Affiliated Hospital School Of Zhejiang University School Of Medicine | Colorectal Neoplasms | Details | |
| Claudin18.2-targeted CAR-T Cells therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine) | Phase 1 Clinical | Second Affiliated Hospital School Of Zhejiang University School Of Medicine | Colorectal Neoplasms | Details | |
| CT-225 | XKDCT225; XKDCT-225; CT225 | Phase 1 Clinical | Shenzhen Celconta Life Science Co Ltd | Solid tumours | Details |
| SIBP-A18 | SIBPA18; SIBP-A18 | Phase 1 Clinical | Shanghai Institute of Biological Products Co Ltd | Solid tumours | Details |
| [68Ga]Ga-NODAGA-SNA014 | 68Ga-SNA014; [68Ga]Ga-NODAGA-SNA014; SNA-014 | Phase 1 Clinical | Smartnuclide Biopharma | Adenocarcinoma; Pancreatic Neoplasms | Details |
| HD-004 | HD004; HD-004 | Phase 1 Clinical | Huadao (Shanghai) Biopharma Co Ltd | Solid tumours | Details |
| SPX-102 | SPX-102 | Phase 1 Clinical | Sparx Therapeutics Inc | Neoplasms | Details |
| Cord Blood-Derived CAR-NK Cells therapy (Rongu Biotechnology) | CB CAR-NK182; RG-CLDN18.2 | Phase 1 Clinical | Hangzhou Rongu Biotechnology Co Ltd | Pancreatic Neoplasms; Stomach Neoplasms | Details |
| LNF-2007 | LNF-2007; LNF2007 | Phase 1 Clinical | Shandong New Time Pharmaceutical Co Ltd | Solid tumours | Details |
| BL-M05D1 | BL-M05D1; BLM05D1 | Phase 1 Clinical | Sichuan Baili Pharmaceutical Co Ltd, SystImmune | Biliary Tract Neoplasms; Carcinoma, Pancreatic Ductal; Esophageal adenocarcinoma; Solid tumours; Stomach Neoplasms | Details |
| AHT-102 | AHT102; AHT-102 | Phase 1 Clinical | Guangxi Lugang Biomedical Technology Co Ltd | Solid tumours | Details |
| AZD-6422 | AZD6422; AZD-6422 | Phase 1 Clinical | Astrazeneca Plc | Gastrointestinal Neoplasms | Details |
| GC-506 | GC506; GC-506 | Phase 1 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Gastroesophageal Junction Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| 68Ga-PMD22(Peking Union Medical College Hospital) | Phase 1 Clinical | Peking Union Medical College Hospital | Gastrointestinal Neoplasms | Details | |
| AK-132 | AK132; AK-132 | Phase 1 Clinical | Neoplasms; Solid tumours | Details | |
| AHT-101 | AHT-101; AHT101 | Phase 1 Clinical | Guangxi Lugang Biomedical Technology Co Ltd | Solid tumours | Details |
| TQB-2103 | TQB2103; TQB-2103 | Phase 1 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Neoplasms | Details |
| BIO-008 | BIO-008 | Phase 1 Clinical | Shijiazhuang Yiling Pharmaceutical Co Ltd | Solid tumours | Details |
| BA-1301 | BA-1301; BA1301 | Phase 1 Clinical | Shandong Boan Biotechnology Co Ltd | Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| RB-0011 | RB0011; RB-0011 | Phase 1 Clinical | Ruiyang (Suzhou) Biological Technology Co Ltd | Solid tumours | Details |
| LB-1904 | LB-1904 | Phase 1 Clinical | Stomach Neoplasms | Details | |
| Ori-C-613 | Ori-C-613; OriC-613; Ori-C613 | Phase 1 Clinical | OriCell Therapeutics Co Ltd | Solid tumours | Details |
| CT-048 | CT-048; KJ-C1807; KJ-C-1807 | Phase 1 Clinical | Carsgen Biomedicine (Shanghai) Co Ltd | Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms | Details |
| ASP-2138 | ASP-2138 | Phase 1 Clinical | Astellas Pharma Global Development Inc, Xencor Inc | Carcinoma, Pancreatic Ductal; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms | Details |
| HEC-016 | HEC-016 | Phase 1 Clinical | People Hospital Of Luohu,Shenzhen | Esophageal Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms | Details |
| PM-3023 | PM-3023 | Phase 1 Clinical | Solid tumours | Details | |
| RD-07 | RD-07 | Phase 1 Clinical | Peking University | Solid tumours | Details |
| IBI-345 | IBI-345 | Phase 1 Clinical | Solid tumours | Details | |
| TORL-2-307-MAB | TORL-2-307-MAB | Phase 1 Clinical | Torl Biotherapeutics LLC | Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| TORL-2-307-ADC | TORL-2-307-ADC | Phase 1 Clinical | Torl Biotherapeutics LLC | Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| BC-008 | BC-008 | Phase 1 Clinical | Dragonboat Biopharmaceutical | Neoplasms; Solid tumours | Details |
| BC-007 (Dragonboat Biopharmaceutical) | BC-007 | Phase 1 Clinical | Dragonboat Biopharmaceutical | Neoplasms; Solid tumours | Details |
| DR-30303 | DR-30303 | Phase 1 Clinical | Zhejiang Doer Biologics Corp | Solid tumours | Details |
| SG-1906 | SG-1906; SG1906 | Phase 1 Clinical | Hangzhou Shangjian Biotechnology Co Ltd | Neoplasms; Solid tumours | Details |
| BA-1105 | BA1105; BA-1105 | Phase 1 Clinical | Shandong Boan Biotechnology Co Ltd | Esophageal Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| CLDN 18.2 CAR-T cell therapy (Shanghai Longyao) | LY-011 | Phase 1 Clinical | Shanghai Longyao Biological Technology Co Ltd | Pancreatic Neoplasms; Stomach Neoplasms | Details |
| IBI-389 | IBI-389 | Phase 1 Clinical | Esophageal Neoplasms; Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details | |
| FL-301 | NBL-015; FL-301 | Phase 1 Clinical | Novarock Biotherapeutics Ltd | Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| IBI-360 | IBI-360 | Phase 1 Clinical | Neoplasms; Solid tumours | Details | |
| QL-1779 | QL-1779; QL1779 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours | Details |
| LM-102 | LM-102 | Phase 1 Clinical | LaNova Medicines Ltd | Biliary Tract Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| HBM-1029 | HBM-1029; HBM1029 | Phase 1 Clinical | Harbour Biomed | Esophageal Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| LCAR-C18S CAR-T cell therapy (Legend) | LB-1908; LCAR-C18S; LCAR-C-18-S | Phase 1 Clinical | Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details | |
| XKDCT-086 | XKDCT086; XKDCT-086 | Clinical | The Affiliated Hospital Of Qingdao University | Stomach Neoplasms | Details |
| CLDN18.2 UCAR-T cell therapy | CLDN18.2 UCAR-T | Clinical | T-Maximum Pharmaceutical (Suzhou) Co Ltd | Stomach Neoplasms | Details |
| 124I-18B10 | 124I-18B10; 124-I-18-B-10 | Clinical | Beijing Cancer Hospital, Transcenta Holding Ltd | Gastrointestinal Neoplasms | Details |
| CTB-001(Nanjing Bioheng) | CTB-001; CTB001 | Clinical | Nanjing Bioheng Biotech Co Ltd | Pancreatic Neoplasms; Stomach Neoplasms | Details |
| 89Zr-NY005 | 89Zr-NY005 | Clinical | Wuxi Nuoyu Pharmaceutical Technology Co Ltd | Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Zolbetuximab | GC-182; iMAB-362; IMAB-362 | Approved | Ganymed | Vyloy, VYLOY, 威络益 | Japan | Stomach Neoplasms | Astellas Pharma Inc | 2024-03-26 | Adenocarcinoma; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Lymphangioma, Cystic; Pain; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to:
Online Message
Contact Us
BettinastraBe 30, 60325 Frankfurt am Main